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published in this issue of the Revista Brasileira de Reumatologia (RBR, Brazilian Journal of Rheumatology). Consensus and guidelines on diagnosis and treatment in Rheumatology have been published for over two decades. During that period, the strategies for elaborating the texts that guide most rheumatologists and clinicians in managing patients with several rheumatic disorders have evolved greatly. In the 'Recommendations' published in this RBR issue, the SBR Committees on Spondyloarthritis and Systemic Sclerosis used strategies for the search and elaboration of the fi nal text from the Projeto Diretrizes da Associação Médica Brasileira (Brazilian Medical Association 'Guideline Project'), which requires that all statements in the text have at least one specifi c reference, graded according to its level of evidence. After the initial elaboration of the text according to pre-established rules and in the 'question and answer' format, some rounds of internet discussion were necessary to refi ne it, before approval by the SBR and Brazilian Medical Association. Both societies showed an excellent partnership to elaborate the fi nal text that would suit the Brazilian reality, without reducing the strength of evidence of the recommendations. With that effi cient partnership, the strength of the recommendations, increasingly based on consistent evidence, will also serve as an instrument to discuss the implantation of governmental strategies for the diagnosis and treatment of rheumatic diseases.
After the new classifi cation criteria for axial 4 and peripheral 5 spondyloarthritis (SpA) issued by the Assessment on SpondyloArthritis International Society (ASAS) group, and the proposition of new guidelines for its treatment, 6, 7 an update of the consensus on the ankylosing spondylitis and psoriatic arthritis treatment, published in the RBR in 2007, 8 Within the SpA spectrum, psoriatic arthritis (PA) has also been increasingly studied over the last two decades, and new classifi cation criteria 9 have been proposed and treatment guidelines, 10 updated. The current Recommendations for the management and treatment of psoriatic arthritis 1 also represent an update of the previous 2007 Brazilian Consensus. 8 The fi rst three questions approach the classifi cation criteria as follows: recommend the CASPAR criteria 9 (Recommendation 1); emphasize the importance of cutaneous, articular and nail assessment (Recommendation 2); and highlight the signifi cant number of comorbidities (Recommendation 3). The conventional treatment assessment comprises questions about the use of the following drugs: corticosteroids (Recommendation 4); NSAIDs (Recommendation 5); and conventional drugs, mainly MTX, cyclosporine, and lefl unomide (Recommendation 6). Seven questions approach the use of biologic agents, especially anti-TNF drugs, as follows: their indication (Recommendation 7); their effi cacy (Recommendation 8); their safety (Recommendation 9); progression of structural damage (Recommendation 10); concomitant use of conventional drugs (Recommendation 11); medication switching (Recommendation 12); and medication duration (Recommendation 13). In addition, one question approaches other biologic drugs (Recommendation 14) and the effi cacy of the drugs acting mainly on the skin over affected joints (Recommendation 15).
One of the most fascinating and complex rheumatologic diseases is the systemic sclerosis (SSc), whose treatment still has to be improved. With the advent of the modern concepts of SSc sine scleroderma, 11 early SSc, 12 and very early SSc, 13 and the establishment of organ-specifi c strategies already outlined in the fi rst Recommendations of Treatment 14 proposed by the EUSTAR (EULAR Scleroderma Trial and Research) group, one can foretell that early diagnosis is essential for therapeutic success. The fi rst three questions approach the diagnosis of SSc (Recommendation 1), the importance of nailfold capillaroscopy (Recommendation 2), and specifi c autoantibodies (Recommendation 3) in the early diagnosis and follow-up of scleroderma patients. Regarding organ-specifi c strategies, there are questions about antifi brotic drugs (Recommendation 4) and the treatment of calcinosis (Recommendation 5). Regarding vascular impairment, there are questions about the treatment of Raynaud's phenomenon (Recommendation 6) and of ischemic ulcers (Recommendation 7), and about the prevention of recurrent ischemic ulcers (Recommendation 8). The most frequent visceral impairment (digestive tract) is also approached on three questions about digestive tract hypomotility (Recommendation 9), gastroesophageal refl ux (Recommendation 10), and malabsorption syndrome (Recommendation 11). The impairment of vital organs is approached in specifi c questions about interstitial lung disease (Recommendation 12), pulmonary arterial hypertension (Recommendation 13), scleroderma renal crisis (Recommendation 14), and cardiac involvement (Recommendation 15).
In conclusion, the new strategy of producing recommendations for the diagnosis and treatment of the major rheumatic diseases, according to the modern rules of the Brazilian Medical Association 'Guideline Project', represents a signifi cant gain in the strength of the SBR recommendations. 
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